- Amphera announces a positive opinion of the European Medicines Agency on the granting of orphan medicinal product designation for MesoPher in pancreatic cancer June 6, 2023
- Alligator Bioscience & Amphera Announce Last Patient Treated in mitazalimab-MesoPher REACTIVE-2 Phase 1 Study in Pancreatic Cancer April 27, 2023
- Amphera announces clinical updates of MesoPher cell therapy December 12, 2022
- Article on the Reactive study in resected pancreatic cancer published in Data in Brief August 4, 2022
- Last patient completed follow-up period in Phase II/III study of Amphera’s MesoPher cell therapy in mesothelioma August 1, 2022
- Article on the results of phase II study with MesoPher in resected pancreatic cancer published in MedNous, June 2022 July 13, 2022
- Amphera’s MesoPher cell therapy demonstrates favourable safety and promising survival in a phase II clinical trial in resected pancreatic cancer May 4, 2022
- First patient enrolled in ENSURE study in resected mesothelioma April 6, 2022
- Amphera progresses two pancreatic cancer programmes after encouraging initial safety and efficacy data in mesothelioma December 8, 2021
- Proof-of-concept Phase I clinical trial started to assess the safety and efficacy of CD40 agonist mitazalimab in combination with MesoPher in patients with progressive metastatic pancreatic cancer November 9, 2021
- DC vaccination-αCD40 combination therapy improves survival of pancreatic tumour-bearing mice June 11, 2021
- DENIM study presented at IMIG2021 May 19, 2021
- DENIM study presented as clinical trial in progress at the virtual WCLC2020 March 11, 2021
- Prof. Casper van Eijck presents first results of REACTIVE study November 26, 2020
- Article on DENIM study in Translational Lung Cancer Research (TLCR) July 12, 2019
- Amphera recruits first patients to phase II study of MesoPher to treat pancreatic cancer May 21, 2019
- Amphera wins top ten list of most groundbreaking innovations in science May 16, 2019
- Amphera presents data of MesoPher and checkpoint inhibitor combination therapy to treat mesothelioma at AACR 2019 April 4, 2019
- Amphera recruits first patients to pivotal phase II/III study of MesoPher to treat pleural mesothelioma March 18, 2019
- ZonMW Parel awarded to prof dr Joachim Aerts for his research on dendritic cell immunotherapy MesoPher for mesothelioma March 15, 2018
- Successful DENIM Consortium Meeting at CHRU Lille March 11, 2018
- World Cancer Day 2018 – Presentation of Prof dr Joachim Aerts on dendritic cell immunotherapy for mesothelioma February 4, 2018
- Dendritic cell immunotherapy is safe and clinically active in mesothelioma December 9, 2016
- Amphera is moving to a new office June 19, 2014
- FDA Orphan Designation granted May 6, 2014
- EMA Orphan Designation granted April 9, 2014
- Amphera is awarded first Red MedTechVentures loan of 350.000 Euro April 8, 2014
- BLSF participates in Amphera B.V. March 1, 2014